Table 1.
Clinical characteristics of the patients.
| IL-6+ (n = 14) | IL-6− (n = 18) | IL-10+ (n = 5) | IL-10− (n = 27) | |
|---|---|---|---|---|
| Age (years) | 65.9 ± 9.2 | 62.4 ± 8.8 | 68.4 ± 9.4 | 63.1 ± 8.9 |
| Sex (M/F) | 8/6 | 9/9 | 4/1 | 13/14 |
| Disease duration (years) | 14.8 ± 8.3 | 15.2 ± 11.5 | 18.4 ± 9.5 | 14.4 ± 10.2 |
| Therapy (oral/insulin/combined) | 7/6/1 | 10/6/2 | 2/3/0 | 15/9/3 |
| BMI (kg/m2) | 30.2 ± 6.9 | 29.3 ± 4.3 | 25.2 ± 3.2* | 30.5 ± 5.5 |
| WC (cm) | 108.4 ± 16.2 | 100.6 ± 10.5 | 97.6 ± 7.2 | 105.2 ± 14.3 |
| Hypertension (yes/no) | 9/5 | 11/7 | 4/1 | 18/9 |
| Hypercholesterolemia (yes/no) | 6/8 | 9/9 | 0/5 | 15/12 |
| Hypertriglyceridemia (yes/no) | 3/11 | 7/11 | 0/5 | 10/17 |
| Pain (yes/no) | 12/2 | 14/4 | 4/1 | 22/5 |
| Pain severity (0–10 NRS) | 2.1 ± 2.3 | 2.5 ± 2.3 | 1.9 ± 1.2 | 2.4 ± 2.4 |
| Serum fasting glucose (mmol/L) | 9.0 ± 2.7 | 9.0 ± 2.8 | 8.4 ± 2.6 | 9.3 ± 2.7 |
| HbA1c (mmol/mol) | 63 ± 14* | 54 ± 12 | 56 ± 8 | 58 ± 16 |
| Creatinine (µmol/L) | 97.2 ± 53.0 | 97.4 ± 61.9 | 106.1 ± 79.6 | 97.2 ± 53.0 |
| UAE (mg/L) | 288 ± 193 | 210 ± 204 | 253 ± 235 | 314 ± 255 |
BMI: body mass index, WC: waist circumference, NRS: numerical rating scale; HbA1c: glycated hemoglobin, and UAE: urinary albumin excretion from spot urine sample. * p < 0.05.